Abstract Body

Follicular helper T ?cells (TFH) are critical for the development of neutralizing antibodies following infection and vaccination. During HIV?1 disease, TFH accumulate in the germinal centers (GC) of lymphoid tissues possibly due to immune activation. Despite this accumulation, only a small percentage of HIV?infected individuals are able to mount a broadly neutralizing response. The drivers of this discrepancy at tissue level remain to be elucidated. We therefore performed a detailed analysis of the immunophenotype, topology and transcriptional signatures of TFH in viremic HIV+ donors with and without evidence of serum neutralizing activity.

LN cell suspensions and matched formalin?fixed, paraffin embedded tissues were analyzed using 30?parameter flow cytometry, quantitative multiplexed confocal imaging and single?cell RNA analysis using the 10x genomics 3´ scRNA?seq kit. Neutralization activity of matched serum samples was determined using a single?round?of?infection Env?pseudotyped virus assay. We classified donors into two groups; non-neutralizers had serum ID50 > 40 for ?1?20 pseudoviruses, while neutralizers had serum ID50 > 40 for at least 6?20 pseudoviruses

Flow cytometric analysis revealed significantly higher frequencies of CD4+ T?cells with a central memory phenotype (CD27hi/loCD45ROhi) in HIV+ neutralizers compared with non?neutralizers (p=0.026) and a concomitant trend for increased TFH (CXCR5hi PD-1hi) in LMNC suspensions and in?situ (CD4hi PD-1hi within CD20hi/dim follicular areas). Higher frequencies of activated (CD95+) ICOS+ and CD57+ expressing TFH were also observed in neutralizers consistent with an increased capacity for optimal T-cell help (p=0.0365). Furthermore, using an unsupervised scRNAseq analysis approach, we observed distinct clustering between non?neutralizer and neutralizer TFH cells driven by 40 differentially expressed genes. Compared to non?neutralizers, neutralizer cells expressed higher levels of FKBP5, IL6ST, CAV-1, IKZF4, GNG4, TRIM8, MYCBP2, TCF7, LIMS1 and FYB1, with associated pathways and TCF7 in particular implying increased potential for self-renewal and differentiation.

Our results suggest distinct phenotypic and transcriptional TFH signatures in the lymph nodes of untreated, chronically HIV-infected individuals with and without neutralizing antibodies which could have implications for the development of future vaccine strategies.